E56: Thankful for Health: AI Vaccines and Weight Loss
KEY TAKEAWAYS
- While AI is a major focus in healthcare, its true impact on drug development is not expected to be fully realized until the 2028-2030 timeframe
- The outlook for the biopharma sector is improving, with a diminished risk of tariffs, a strong drug pipeline and expectations for continued M&A activity creating a positive environment for 2026 and 2027
- The next major innovation in weight loss will be oral GLP-1 drugs, like Lilly's Orforglipron expected in early 2026, which could become a "game changer" by creating a large, consumer-focused cash-pay market
Anne Malone, Head of North America Equity Research, and Global Head of Healthcare Geoff Meacham discuss where Healthcare stands after the third-quarter reporting period. Conversation topics include the promise of AI, innovations in the drug pipeline and the next phase of GLP-1s.
This podcast contains thematic content and is not intended to be investment research. Nor does it constitute financial, economic, legal, tax or accounting advice. This podcast is provided for information purposes only and does not constitute an offer or solicitation to purchase or sell any financial instruments. The contents of this podcast are not based on your individual circumstances and should not be relied upon as an assessment of suitability for you of a particular product, security, or transaction. The information in this podcast is based on generally available information and, although obtained from sources believed by Citi to be reliable, its accuracy and completeness are not guaranteed. Past performance is not a guarantee or indication of future results. This podcast may not be copied or distributed, in whole or in part, without the express written consent of Citi. © 2025 Citigroup Global Markets Inc. Member SIPC. All rights reserved. Citi and Citi and Arc Design are trademarks and service marks of Citigroup Inc. or its affiliates and are used and registered throughout the world.
Anne Malone, Head of North America and Latin America Equity, Citi Research
Anne Malone was named Head of North America and Latin America Equity Research 2022; promoted from Deputy Director, a role she held since 2018. Anne started at the firm in 1996 as an Analyst covering Medical Technology stocks. She has held several positions since then, in both Equity Research and Citi Asset Management, taking on roles that utilized her analytical, product, and people skills. Prior to joining Citi she was a Medical Device Analyst at Bear Stearns. Anne graduated from the St Leo College with a degree in Finance and a minor in Economics. She is a CFA Charterholder.
Geoff Meacham, Global Head of Healthcare, Citi Research
Geoff Meacham, Ph.D. is a Managing Director at Citi Research, covering both the US Pharmaceuticals and Biotechnology sectors. Prior to joining Citi in September 2024, Geoff covered the Pharma / Biotechnology sectors for 20+ years at Bank of America and Barclays, as well as JP Morgan Chase and UBS. Prior to joining Wall Street, Geoff conducted R&D at Solvay Pharmaceuticals. He is based in Atlanta.
